ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys
Provided By GlobeNewswire
Last update: Jun 26, 2025
Reduction in Force Estimated to Save Over $750K or 23.4% of Annual Payroll Expenses
Agreements Progress Toward Completion; Shareholder Meeting Scheduled for July 24, 2025
Read more at globenewswire.com
